Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Comprehensive List of Current Guidance Documents at the Food and Drug Administration | General comments on this list and on agency guidance documents are welcome at any time. | ||
| View | Prospective Grant of Exclusive License: Method of Determining the Presence of Functional p53 in Mammalian Cells | Only written comments and/or applications for a license which are received by NIH on or before May 11, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Dynamically Stable Associative Learning Neural Network System | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 9, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Pharmaceutical Compositions And Methods For Treatment of Hyperproliferative Epithelial Skin Diseases and Cancer | Only written comments and/or applications for a license which are received by NIH on or before March 23, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Promotion of Homologous Recombination DNA Pairing by RecA And RecA Peptides | Only written comments and/or applications for a license which are received by NIH on or before February 10, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Therapeutic Uses of Blood Vessel Growth Promoting Peptides Including Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (FGF) for Cardiovascular Disease and Conditions Such as Myocardial Ischemia | Only written comments and/or applications for a license which are received by NIH on or before February 9, 1998 will be considered. | ||
| View | National Cancer Institute; Opportunity for a Cooperative Research and Development Agreement (CRADA) for the Scientific and Commercial Development of Transgenic Mice That Express Human Cytochrome P450 Genes | In view of the important priority of developing new drugs for the treatment of cancer and methods for determining carcinogenic risk, interested parties should notify this office in writing not later that January 2, 1998. Respondents will then be provided an additional 30 days for filing of formal proposals. | ||
| View | Prospective Grant of Exclusive License: Pigment Epithelium Derived Growth Factor | Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Immunodampening Technology | Only written comments and/or applications for a license which are received by NIH on or before February 17, 1998 will be considered. | ||
| View | Prospective Grant of Exclusive License: Synthetic, Anti- Complement Protein and Gene Useful in Transplant Therapeutics | Only written comments and/or applications for a license which are received by NIH on or before December 26, 1997 will be considered. | ||
| View | Prospective Grant of Exclusive License: IL-4 Pseudomonas Exotoxin Fusion Protein Therapeutics | Only written comments and/or applications for a license which are received by NIH on or before January 26, 1998 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Limited Exclusive License: Monoclonal Antibodies to Thymidylate Synthase | Only written comments and/or applications for a license which are received by NIH on or before November 18, 1997 will be considered. | ||
| View | National Cancer Institute: Opportunities for Cooperative Research and Development Agreements (CRADAs) for the Development of New Targeted Drugs, Made Partly of Entities Provided by the National Cancer Institute (NCI), as Treatments for Patients With Cancer | Organizations must submit a confidential proposal summary preferably one page or less, to NCI within 90 days from date of this publication. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents with whom initial confidential discussions will have established sufficient mutual interest. | ||
| View | Prospective Grant of Exclusive License: For Nucleic Acid-Based Vaccines and Therapeutics | Only written comments and/or applications for a license which are received by NIH on or before December 9, 1997 will be considered. | ||
| View | Prospective Grant of Exclusive License: Biomedical Uses of Topoisomerase I Inhibitors Including Camptothecin and Derivatives for Retroviral Applications Including Human Immunodeficiency Virus (HIV) | Only written comments and/or applications for a license which are received by NIH on or before October 20, 1997 will be considered. | ||
| View | Notice of CRADA Opportunities | Inquiries regarding scientific matters may be forwarded at any time. Confidential CRADA proposals, preferably one page or less, must be submitted to NCI on or before October 10, 1997. Guidelines for preparing full CRADA proposals will be communicated shortly thereafter to all respondents who have been selected. | ||
| View | Prospective Grant of Exclusive License: Diagnostic Methods Derived From the Human Metastasis Suppressor Gene KAI1 | Only written comments and/or applications for a license which are received by NIH on or before October 10, 1997. | ||
| View | Prospective Grant of Exclusive License: New Brefeldin a Derivatives | Only written comments and/or applications for a license which are received by NIH on or before October 10, 1997, will be considered. | ||
| View | Prospective Grant of Limited Exclusive License: Radioimmunotherapy Utilizing Bismuth 213 and Monoclonal Antibodies Having Binding Specificity to Tag-72 and Human Carcinomas | Only written comments and/or applications for a license which are received by NIH on or before July 28, 1997 will be considered. | ||
| View | Opportunity for a Cooperative Research and Development Agreement (CRADA) and Licensing Opportunity for Testosterone Bucyclate | In view of the high priority for developing and commercializing testosterone bucyclate, all proposals must be received no later than June 26, 1997 for priority consideration. | ||
| View | Prospective Grant of Exclusive License: Vaccine for Malaria | |||
| View | Prospective Grant of Exclusive License: Prophylactic Use of Pneumococcal Surface Adhesin A Protein as a Vaccine | 09/17/91 Domestic Status: Patent No.: 5,422,427 Issue Date: 06/06/95 | ||
| View | Prospective Grant of Exclusive License: Treatment of Cancer Using Human Chorionic Gonadotropin (hCG) | |||
| View | Propspective Grant of Exclusive License: Method of Identifying Persons Susceptible to Autoimmune Neuropsychiatric Disorders |